| UniProt ID | CCND3_HUMAN | |
|---|---|---|
| UniProt AC | P30281 | |
| Protein Name | G1/S-specific cyclin-D3 | |
| Gene Name | CCND3 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 292 | |
| Subcellular Localization | Nucleus . Cytoplasm . Membrane . Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members.. | |
| Protein Description | Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.. | |
| Protein Sequence | MELLCCEGTRHAPRAGPDPRLLGDQRVLQSLLRLEERYVPRASYFQCVQREIKPHMRKMLAYWMLEVCEEQRCEEEVFPLAMNYLDRYLSCVPTRKAQLQLLGAVCMLLASKLRETTPLTIEKLCIYTDHAVSPRQLRDWEVLVLGKLKWDLAAVIAHDFLAFILHRLSLPRDRQALVKKHAQTFLALCATDYTFAMYPPSMIATGSIGAAVQGLGACSMSGDELTELLAGITGTEVDCLRACQEQIEAALRESLREASQTSSSPAPKAPRGSSSQGPSQTSTPTDVTAIHL | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 9 | Phosphorylation | ELLCCEGTRHAPRAG CEEECCCCCCCCCCC | 9.29 | - | |
| 30 | Phosphorylation | GDQRVLQSLLRLEER CCHHHHHHHHHHHHH | 25.80 | 24719451 | |
| 38 | Phosphorylation | LLRLEERYVPRASYF HHHHHHHHCCCHHHH | 20.34 | 26657352 | |
| 43 | Phosphorylation | ERYVPRASYFQCVQR HHHCCCHHHHHHHHH | 27.97 | 26657352 | |
| 123 | Ubiquitination | TTPLTIEKLCIYTDH CCCCEEHHHHHHCCC | 44.82 | - | |
| 133 | Phosphorylation | IYTDHAVSPRQLRDW HHCCCCCCHHHCCCC | 18.36 | 24719451 | |
| 169 | Phosphorylation | AFILHRLSLPRDRQA HHHHHHCCCCHHHHH | 35.96 | 24719451 | |
| 259 | Phosphorylation | RESLREASQTSSSPA HHHHHHHHHCCCCCC | 29.28 | 28450419 | |
| 261 | Phosphorylation | SLREASQTSSSPAPK HHHHHHHCCCCCCCC | 28.25 | 28450419 | |
| 262 | Phosphorylation | LREASQTSSSPAPKA HHHHHHCCCCCCCCC | 22.60 | 29255136 | |
| 263 | Phosphorylation | REASQTSSSPAPKAP HHHHHCCCCCCCCCC | 43.67 | 29255136 | |
| 264 | Phosphorylation | EASQTSSSPAPKAPR HHHHCCCCCCCCCCC | 25.50 | 29255136 | |
| 273 | Phosphorylation | APKAPRGSSSQGPSQ CCCCCCCCCCCCCCC | 28.26 | 28851738 | |
| 274 | Phosphorylation | PKAPRGSSSQGPSQT CCCCCCCCCCCCCCC | 29.51 | 22617229 | |
| 275 | Phosphorylation | KAPRGSSSQGPSQTS CCCCCCCCCCCCCCC | 40.63 | 28851738 | |
| 279 | Phosphorylation | GSSSQGPSQTSTPTD CCCCCCCCCCCCCCC | 53.57 | 22617229 | |
| 281 | Phosphorylation | SSQGPSQTSTPTDVT CCCCCCCCCCCCCCE | 38.62 | 28450419 | |
| 282 | Phosphorylation | SQGPSQTSTPTDVTA CCCCCCCCCCCCCEE | 25.42 | 22617229 | |
| 283 | Phosphorylation | QGPSQTSTPTDVTAI CCCCCCCCCCCCEEE | 33.33 | 25159151 | |
| 285 | Phosphorylation | PSQTSTPTDVTAIHL CCCCCCCCCCEEECC | 43.09 | 28450419 | |
| 288 | Phosphorylation | TSTPTDVTAIHL--- CCCCCCCEEECC--- | 23.78 | 28450419 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 283 | T | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
| 283 | T | Phosphorylation | Kinase | MAPK11 | Q15759 | GPS |
| 283 | T | Phosphorylation | Kinase | MAPK12 | P53778 | GPS |
| 283 | T | Phosphorylation | Kinase | MAPK13 | O15264 | GPS |
| - | K | Ubiquitination | E3 ubiquitin ligase | FBXL2 | Q9UKC9 | PMID:22024926 |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CCND3_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CCND3_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| H00010 | Multiple myeloma | |||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-279, AND MASSSPECTROMETRY. | |
| "Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND MASSSPECTROMETRY. | |